Finasteride Tablets
Awarded Award Notice Posted
- Solicitation number
- SPE2D218R0028
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Awarded
- to Exelan Pharmaceuticals Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- SPE2D2-19-D-0070 Federal IDV award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical awarded a contract to Exelan Pharmaceuticals Inc. on May 29, 2019 to supply finasteride tablets. The original contract value was $43,744,593.55 for supplying this pharmaceutical product to the agency. Over the course of several modifications and exercised option years between 2019 and 2023, the total contract value remained $43,744,593.55 for Exelan to provide the Defense Logistics Agency Troop Support Medical with finasteride tablets.
Notice text
6 versions
Update #6 · Latest ·
Modification SPE2D2-19-D-0070 P00010 to incorporate Drug Supply Chain Act (DSCA) language into soliciations for subjec contract.
Modification SPE2D2-19-D-0070 P00009 to incorporate FAR 52.204-27 Prohibition on a Bytedance Covered Application (June 2023) into contract.
Modification to excercise Option Year 4 for Finasteride Tablets SPE2D2-19-D-0070 effective May 29, 2023 through May 28, 2024.
Modification to excercise Option Year 3 for Finasteride Tablets SPE2D2-19-D-0070 effective May 29, 2022 through May 28, 2023.
EXERCISE OF OPTION YEAR 1
Awarded contract SPE2D2-19-D-0070 to Exelan Pharmaceuticals Inc for 43744593.55 on 2019-05-29.
Update #5 ·
Modification to excercise Option Year 4 for Finasteride Tablets SPE2D2-19-D-0070 effective May 29, 2023 through May 28, 2024.
Modification to excercise Option Year 3 for Finasteride Tablets SPE2D2-19-D-0070 effective May 29, 2022 through May 28, 2023.
EXERCISE OF OPTION YEAR 1
Awarded contract SPE2D2-19-D-0070 to Exelan Pharmaceuticals Inc for 43744593.55 on 2019-05-29.
Update #4 ·
Modification to excercise Option Year 3 for Finasteride Tablets SPE2D2-19-D-0070 effective May 29, 2022 through May 28, 2023.
EXERCISE OF OPTION YEAR 1
Awarded contract SPE2D2-19-D-0070 to Exelan Pharmaceuticals Inc for 43744593.55 on 2019-05-29.
Update #3 ·
EXERCISE OF OPTION YEAR 1
Awarded contract SPE2D2-19-D-0070 to Exelan Pharmaceuticals Inc for 43744593.55 on 2019-05-29.
Update #2 ·
Awarded contract SPE2D2-19-D-0070 to Exelan Pharmaceuticals Inc for 43744593.55 on 2019-05-29.
Update #1 ·
Awarded contract SPE2D2-19-D-0070 to Exelan Pharmaceuticals Inc for $43,744,593.55 on 2019-05-29.
Attachments
| File | Type | Posted |
|---|---|---|
| Signed SPE2D219D0070 P00010 Finasteride.pdf | ||
| SF30_SPE2D219D0070P00009.PDF | ||
| Modification Option Year 4 P00008 SPE2D2-19-D-0070.pdf | ||
| Modification Option Year 3 P00007 SPE2D219D0070.PDF | ||
| SPE2D219D0070P00004.pdf | ||
| SPE2D219D0070P00002.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Finasteride Tablets | Award Notice | |
| Finasteride tablets national contract | Solicitation | |
| Finasteride Tablets | Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity